{"protocolSection":{"identificationModule":{"nctId":"NCT01165021","orgStudyIdInfo":{"id":"13621"},"secondaryIdInfos":[{"id":"H3E-EW-JMIP","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer","officialTitle":"An Exploratory Phase 2 Study of Pemetrexed/Cisplatin as Pre-operative Chemotherapy in the Treatment of Stage IIIAN2 Nonsquamous Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2019-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-11"},"primaryCompletionDateStruct":{"date":"2013-07","type":"ACTUAL"},"completionDateStruct":{"date":"2016-04","type":"ACTUAL"},"studyFirstSubmitDate":"2010-07-14","studyFirstSubmitQcDate":"2010-07-16","studyFirstPostDateStruct":{"date":"2010-07-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-04-23","resultsFirstSubmitQcDate":"2014-04-23","resultsFirstPostDateStruct":{"date":"2014-05-21","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-09-10","lastUpdatePostDateStruct":{"date":"2019-09-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this trial is to assess how well the combination of pemetrexed with cisplatin can reduce tumor size."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":19,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed + Cisplatin","type":"EXPERIMENTAL","interventionNames":["Drug: Pemetrexed","Drug: Cisplatin","Drug: Folic Acid","Drug: Vitamin B12","Drug: Dexamethasone"]}],"interventions":[{"type":"DRUG","name":"Pemetrexed","description":"500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles","armGroupLabels":["Pemetrexed + Cisplatin"],"otherNames":["Alimta","LY231514"]},{"type":"DRUG","name":"Cisplatin","description":"75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles","armGroupLabels":["Pemetrexed + Cisplatin"]},{"type":"DRUG","name":"Folic Acid","description":"Administered orally.","armGroupLabels":["Pemetrexed + Cisplatin"]},{"type":"DRUG","name":"Vitamin B12","description":"Administered Intramuscular injection.","armGroupLabels":["Pemetrexed + Cisplatin"]},{"type":"DRUG","name":"Dexamethasone","description":"Administered orally.","armGroupLabels":["Pemetrexed + Cisplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]","description":"Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. CR was defined as the disappearance of all target and non-target lesions and all target and non-target lymph nodes were non-pathological or normal in size \\[\\<10 millimeter (mm) short axis\\]. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameters. ORR calculated as: (sum of the number of participants with PRs and CRs) divided by (number of evaluable participants) multiplied by 100.","timeFrame":"From study enrollment until disease progression or recurrence up to completion of 3 cycles (21-day cycles) of chemotherapy"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With No Viable Tumor Cells in Resected Lung Tissue [Pathological Complete Remission (pCR)]","description":"pCR after the participant has undergone surgery was calculated as: (total number of participants with pCR) divided by (the total number of participants in pathological response population) multiplied by 100.","timeFrame":"At the time of surgery (within 3 to 6 weeks of Day 1 of Cycle 3 [21-day cycles] of chemotherapy)"},{"measure":"Percentage of Participants Who Exhibit a Downward Shift in Tumor Extent From Stage IIIAN2 to Stages IIIA, II, I, or Stage 0","description":"Tumor downstaging compared to baseline (Stage IIIAN2) were those participants who exhibited a downward shift in tumor extent from Stage IIIAN2 to Stages IIIA, II, I, or 0 were reported. Downstaging was based on radiological examination. Stage IIIAN2 was locally advanced and/or involved lymph nodes, metastasis in ipsilateral mediastinal and or subcarinal lymph nodes, tumors were ≤2 centimeters (cm) up to 5 cm in greatest dimension; Stage IIIA was locally advanced and/or involved lymph nodes, tumor extension was restricted to the affected lung; Stage II was locally advanced and/or involved lymph nodes; Stage I was small localized cancers, usually curable; Stage 0 the cancer did not spread beyond the inner lining of the lung. Missing responses were also reported. Percentage of participants calculated as: (number of participants with a downward shift in extent of their tumor) divided by (total number of evaluable participants) multiplied by 100.","timeFrame":"From study enrollment until disease progression or recurrence up to completion of 3 cycles (21-day cycles) of chemotherapy"},{"measure":"Overall Survival (OS)","description":"OS was defined as duration from the date of study enrollment to the date of death from any cause. Participants not known to have died as of the data inclusion cut-off date were censored at the date of last contact. The last contact for participants in post-discontinuation was the last date participant was known to be alive.","timeFrame":"Enrollment until the date of death from any cause up to 64 months"},{"measure":"Progression-Free Survival (PFS)","description":"PFS was defined as the time from date of first dose to the first observation of disease progression or death due to any cause. For participants not known to have died or did not have objective progressive disease (PD) as of the data inclusion cut-off date, PFS was censored at the date of the last objective progression-free disease assessment. PD was defined using RECIST v1.1 criteria as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.","timeFrame":"Enrollment until the first date of objectively determined PD or death up to 64 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Nonsquamous Non-Small Cell Lung Cancer that was confirmed by tissue biopsy\n* Stage IIIAN2 disease (T1aN2, T1bN2, T2aN2, T2bN2, and T3N2)\n* Tumor considered potentially resectable\n* Good performance status (score of 0 or 1) according to Eastern Cooperative Oncology Group scale (ECOG)\n* No prior therapy for lung cancer\n* Measurable disease according to version 1.1 of Response Evaluation Criteria in Solid Tumors (RECIST) Criteria\n* Life expectancy of at least 6 months\n* Organs are functioning well (bone marrow reserve, liver, kidney, lung)\n* Signed Informed Consent\n* Women must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen (for example, intrauterine device, birth control pills, or barrier device) during and for 6 months after last dose of study drug; must have a negative pregnancy test within 7 days before study enrollment; and must not be breast-feeding.\n* Men must be surgically sterile, or compliant with a contraceptive regimen during and for 6 months after last dose of study drug.\n* Be fit for surgery at the time of enrollment\n\nExclusion Criteria:\n\n* Receiving or have received an investigational drug or device within the last 30 days\n* Have previously completed or withdrawn from this study or any other study investigating pemetrexed\n* Serious concomitant systemic disorder\n* Serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease\n* Receiving concurrent administration of any other anticancer therapy\n* Have received a recent (within 30 days of enrollment) or are receiving concurrent yellow fever vaccination\n* Inability or unwillingness to take Pemetrexed supplementation/premedication (folic acid, vitamin B12, or corticosteroids)\n* Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose less than or equal to 1.3 grams per day","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Milan","zip":"20133","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Novara","zip":"28100","country":"Italy","geoPoint":{"lat":45.44694,"lon":8.62118}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Orbassano","zip":"10043","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Padua","zip":"35100","country":"Italy","geoPoint":{"lat":45.40797,"lon":11.88586}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pisa","zip":"56100","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Rome","zip":"00144","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Sondalo","zip":"23039","country":"Italy","geoPoint":{"lat":46.32983,"lon":10.3269}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Participant Flow reports participants who discontinued from study treatment. Completed participants were those who had a baseline tumor assessment, finished 3 cycles (Cy) of pre-operative chemotherapy (chemo), and had a second tumor assessment following chemo.","groups":[{"id":"FG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles\n\nCisplatin: 75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"19"}]},{"type":"≥1 Dose Chemo","achievements":[{"groupId":"FG000","numSubjects":"19"}]},{"type":"≥1 Dose Chemo, Baseline, Cy 3 Assessment","achievements":[{"groupId":"FG000","numSubjects":"17"}]},{"type":"3 Cycles of Chemo, Then Surgery","achievements":[{"groupId":"FG000","numSubjects":"15"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"18"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All participants who received at least 1 dose of chemotherapy.","groups":[{"id":"BG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles\n\nCisplatin: 75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"19"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"62.5","spread":"9.32"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"6"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"13"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Italy","categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"ECOG classifies participants according to their functional impairment. Scores range from 0 (fully active) to 5 (death). 0 (fully active, able to carry on all pre-disease performance without restriction) and 1 (restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature).","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"0","categories":[{"measurements":[{"groupId":"BG000","value":"15"}]}]},{"title":"1","categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}]}]},{"title":"Initial Pathological Diagnosis","description":"Initial cancer diagnosis confirmed by tissue biopsy.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Adenocarcinoma, Lung","categories":[{"measurements":[{"groupId":"BG000","value":"17"}]}]},{"title":"Carcinoma, Large Cell, Lung","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]},{"title":"Carcinoma, Non-Small Cell, Lung","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Tumor-Node-Metastasis (TNM) Stage of Disease","description":"Tumor size: T1=surrounded by lung or visceral pleura with no evidence of invasion more proximal than lobar bronchus; T1a ≤2 centimeters (cm) at greatest dimension (GD); T1b \\>2 cm, ≤3 cm at GD; T2=involves main bronchus, ≥2 cm distal to carina; invades visceral pleura, associated with atelectasis or obstructive pneumonitis extends to hilar but not entire lung; T2a \\>3 cm, ≤5 cm at GD; T2b \\>5 cm, ≤7 cm at GD; T3= \\>7 cm or 1 that invades the thoracic cavity. Nodal status (N): N2 =Metastasis in ipsilateral mediastinal and/or subcarinal lymph nodes. Distant metastasis (M): M0 =No distant metastasis.","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"T1aN2M0","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]},{"title":"T1bN2M0","categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}]},{"title":"T2aN2M0","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]},{"title":"T2bN2M0","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]},{"title":"T3N2M0","categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}]}]},{"title":"Tobacco Consumption Status","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Current Tobacco User","categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}]},{"title":"Former Tobacco User","categories":[{"measurements":[{"groupId":"BG000","value":"12"}]}]},{"title":"Never Used Tobacco","categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]","description":"Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. CR was defined as the disappearance of all target and non-target lesions and all target and non-target lymph nodes were non-pathological or normal in size \\[\\<10 millimeter (mm) short axis\\]. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameters. ORR calculated as: (sum of the number of participants with PRs and CRs) divided by (number of evaluable participants) multiplied by 100.","populationDescription":"Participants who received at least 1 dose of preoperative chemotherapy and had baseline and Cycle 3 scans for tumor assessment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From study enrollment until disease progression or recurrence up to completion of 3 cycles (21-day cycles) of chemotherapy","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles\n\nCisplatin: 75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","lowerLimit":"18.4","upperLimit":"67.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With No Viable Tumor Cells in Resected Lung Tissue [Pathological Complete Remission (pCR)]","description":"pCR after the participant has undergone surgery was calculated as: (total number of participants with pCR) divided by (the total number of participants in pathological response population) multiplied by 100.","populationDescription":"Participants who received at least 1 dose of preoperative chemotherapy and had surgical tumor tissue samples available.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"At the time of surgery (within 3 to 6 weeks of Day 1 of Cycle 3 [21-day cycles] of chemotherapy)","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles\n\nCisplatin: 75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3","lowerLimit":"68.1","upperLimit":"99.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Exhibit a Downward Shift in Tumor Extent From Stage IIIAN2 to Stages IIIA, II, I, or Stage 0","description":"Tumor downstaging compared to baseline (Stage IIIAN2) were those participants who exhibited a downward shift in tumor extent from Stage IIIAN2 to Stages IIIA, II, I, or 0 were reported. Downstaging was based on radiological examination. Stage IIIAN2 was locally advanced and/or involved lymph nodes, metastasis in ipsilateral mediastinal and or subcarinal lymph nodes, tumors were ≤2 centimeters (cm) up to 5 cm in greatest dimension; Stage IIIA was locally advanced and/or involved lymph nodes, tumor extension was restricted to the affected lung; Stage II was locally advanced and/or involved lymph nodes; Stage I was small localized cancers, usually curable; Stage 0 the cancer did not spread beyond the inner lining of the lung. Missing responses were also reported. Percentage of participants calculated as: (number of participants with a downward shift in extent of their tumor) divided by (total number of evaluable participants) multiplied by 100.","populationDescription":"Participants who received at least 1 dose of preoperative chemotherapy and had baseline and Cycle 3 scans for tumor assessment.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"From study enrollment until disease progression or recurrence up to completion of 3 cycles (21-day cycles) of chemotherapy","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles\n\nCisplatin: 75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"classes":[{"title":"No Change or Worsening of Tumor Stage","categories":[{"measurements":[{"groupId":"OG000","value":"29.4","lowerLimit":"10.3","upperLimit":"56.0"}]}]},{"title":"Change to Stage IIIA","categories":[{"measurements":[{"groupId":"OG000","value":"29.4","lowerLimit":"10.3","upperLimit":"56.0"}]}]},{"title":"Change to Stage II","categories":[{"measurements":[{"groupId":"OG000","value":"11.8","lowerLimit":"1.5","upperLimit":"36.4"}]}]},{"title":"Change to Stage I","categories":[{"measurements":[{"groupId":"OG000","value":"17.6","lowerLimit":"3.8","upperLimit":"43.4"}]}]},{"title":"Missing","categories":[{"measurements":[{"groupId":"OG000","value":"11.8","lowerLimit":"1.5","upperLimit":"36.4"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as duration from the date of study enrollment to the date of death from any cause. Participants not known to have died as of the data inclusion cut-off date were censored at the date of last contact. The last contact for participants in post-discontinuation was the last date participant was known to be alive.","populationDescription":"All participants who received 1 or more doses of preoperative chemotherapy. Participants censored=8","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Enrollment until the date of death from any cause up to 64 months","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles\n\nCisplatin: 75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.6","lowerLimit":"10.8","upperLimit":"NA","comment":"Upper range of 95% confidence interval were not calculated due to high censoring rate."}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"PFS was defined as the time from date of first dose to the first observation of disease progression or death due to any cause. For participants not known to have died or did not have objective progressive disease (PD) as of the data inclusion cut-off date, PFS was censored at the date of the last objective progression-free disease assessment. PD was defined using RECIST v1.1 criteria as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (including the baseline sum if that is the smallest). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.","populationDescription":"All participants who received 1 or more doses of preoperative chemotherapy. Participants censored=3.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Enrollment until the first date of objectively determined PD or death up to 64 months","groups":[{"id":"OG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 milligrams per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles\n\nCisplatin: 75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.4","lowerLimit":"7.0","upperLimit":"21.7"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Pemetrexed + Cisplatin","description":"Pemetrexed: 500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles\n\nCisplatin: 75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles","seriousNumAffected":2,"seriousNumAtRisk":19,"otherNumAffected":15,"otherNumAtRisk":19}],"seriousEvents":[{"term":"Acute abdomen","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Paraneoplastic syndrome","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Apical granuloma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":19}]},{"term":"Oral dysaesthesia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":19}]},{"term":"Irritability","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Anaemia postoperative","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":19}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":19}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Depressive symptom","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Cystitis noninfective","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Cafe au lait spots","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":19}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Due to difficulties identifying suitable participants and enrollment delays, entries were closed after 26 of planned 33 participants signed consent. Results based on 19 participants who received ≥1 dose of chemotherapy. View results with caution."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D002945","term":"Cisplatin"},{"id":"D005492","term":"Folic Acid"},{"id":"D014805","term":"Vitamin B 12"},{"id":"D003907","term":"Dexamethasone"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D011622","term":"Pterins"},{"id":"D011621","term":"Pteridines"},{"id":"D045728","term":"Corrinoids"},{"id":"D045725","term":"Tetrapyrroles"},{"id":"D011758","term":"Pyrroles"},{"id":"D001393","term":"Azoles"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006576","term":"Heterocyclic Compounds, 4 or More Rings"},{"id":"D047028","term":"Macrocyclic Compounds"},{"id":"D011083","term":"Polycyclic Compounds"},{"id":"D011246","term":"Pregnadienetriols"},{"id":"D011245","term":"Pregnadienes"},{"id":"D011278","term":"Pregnanes"},{"id":"D013256","term":"Steroids"},{"id":"D000072473","term":"Fused-Ring Compounds"},{"id":"D013259","term":"Steroids, Fluorinated"}]}},"hasResults":true}